Table 1 Selected demographic and clinical characteristics of rheumatoid arthritis patients stratified by the presence of ischaemic heart disease
Variable | All patients (n= 414) | Patients without IHD (n= 328) | Patients with IHD (n= 86) | Pvaluea |
|---|---|---|---|---|
Age, years | 62.0 (54.8-69.0) | 61.0 (54.0-68.0) | 67.0 (58.0-72.3) | < 0.0001 |
Age of onset, years | 50.0 (41.0-58.0) | 49.0 (40.0-56.2) | 54.9 (44.3-63.2) | 0.0022 |
Duration, years | 10.0 (3.6-18.0) | 10.0 (3.0-18.0) | 8.0 (4.0-18.0) | NS |
Male/female | 136/278 | 91/237 | 45/41 | < 0.0001 |
Body mass index | 27.3 (24.6-30.4) | 27.3 (24.4-30.3) | 27.4 (25.4-31.0) | NS |
Rheumatoid factor | 236/412 (57.3%) | 178/326 (54.6%) | 58/86 (67.4%) | 0.032 |
Anti-CCP | 305/402 (75.9%) | 243/320 (75.9%) | 62/82 (75.6%) | NS |
ESR | 20 (10-37) | 18 (10-34) | 26 (10-43.5) | NS |
CRP (≥ 10 mg/L) | 223/414 (53.9%) | 162/328 (49.4%) | 61/86 (70.9%) | 0.0004 |
Nodules | 54/414 (13.0%) | 41/328 (12.5%) | 13/86 (15.1%) | NS |
Erosions | 301/407 (74.0%) | 243/322 (75.5%) | 58/85 (68.2%) | NS |
DAS28b | 4.2 (1.4%) | 4.1 (1.4%) | 4.4 (1.4%) | NS |
HAQ score | 1.6 (1.0-2.0) | 1.6 (0.9-2.0) | 1.8 (1.3-2.3) | 0.014 |
Ever-smoker | 276/414 (66.7%) | 205/328 (62.5%) | 71/86 (82.6%) | 0.0004 |
Current smoker | 74/414 (17.9%) | 58/328 (17.7%) | 16/86 (18.6%) | NS |
Previous MI | 52/414 (12.6%) | - | 52/86 (60.5%) | - |
Hypertension | 161/413 (39.0%) | 110/327 (33.6%) | 51/86 (59.3%) | < 0.0001 |
Hypercholesterolemia | 68/414 (16.4%) | 39/328 (11.9%) | 29/86 (33.7%) | < 0.0001 |
Diabetes (I and II) | 30/414 (7.3%) | 13/328 (4.0%) | 17/86 (19.8%) | < 0.0001 |
DMARD use | 386/413 (93.5%) | 306/327 (93.6%) | 80/86 (93.0%) | NS |
Methotrexate use | 242/413 (58.6%) | 204/327 (62.4%) | 38/86 (44.2%) | 0.0023 |
Steroid use | 40/413 (9.7%) | 28/327 (8.6%) | 12/86 (14.0%) | NS |
Biologic agent use | 60/413 (14.5%) | 53/327 (16.2%) | 7/86 (8.1%) | NS |
Serum TGF-β1 level, pg/mL | 16,908 (12,744-21,428) | 16,764 (12,422-21,772) | 17,156 (13,435-20,533) | NS |